Idorsia Ltd (SIX: IDIA) is set to present new findings on daridorexant, a dual orexin receptor antagonist, at Sleep Europe 2026, which will take place in Maastricht, the Netherlands, from October 20 to 23, 2026. This includes the first Phase 2 study focusing on pediatric insomnia disorder, representing the only investigational data for a dual orexin receptor antagonist in children. The study results will be shared in a late-breaking session dedicated to influential clinical trials.
Read More
The research indicated that pediatric insomnia can severely impact sleep quality, daytime functioning, academic performance, and overall quality of life, particularly for children with neurodevelopmental disorders such as Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD). There are limited pharmacological options available for treating pediatric insomnia, with no approved medications in the U.S. and only prolonged-release melatonin authorized in certain pediatric cases in Europe.
The Phase 2 trial assessed three dosages of daridorexant—10 mg, 25 mg, and 50 mg—in children aged 10 to under 18 years diagnosed with insomnia disorder, including those with neurodevelopmental disorders. The findings, which extend understanding of orexin signaling in a younger population, will be detailed by Professor Carmen M. Schröder in the "Impactful Clinical Trial Session II" on October 23.
In addition to the pediatric study, there will be presentations on real-world evidence evaluating daridorexant's impact on insomnia treatment outcomes, including sleep quality, daytime functioning, quality of life, and work productivity.
Interim results from the ProDiGyA study in Germany and Austria will reveal how daridorexant affects real-world treatment patterns and insomnia severity during the initial months of treatment. Results from a Canadian noninterventional study will focus on the drug's influence on quality of life and work productivity for insomnia patients.
Moreover, a new analysis from a pivotal Phase 3 study will evaluate the drug's efficacy and safety concerning short sleep duration in adults. Evaluations across six countries will investigate how the introduction of dual orexin receptor antagonists has modified the usage of traditional sedative-hypnotics and the associated healthcare policies affecting their adoption.
At least six investigator-initiated studies on daridorexant will also be presented, addressing its effects on various populations, including menopausal women and patients with epilepsy or major depressive disorder. These collective efforts aim to enhance understanding of insomnia management and contribute to the evolving landscape of treatment options.
Sleep Europe 2026 brings together over 3,000 professionals in the field of sleep medicine and research, facilitating discussions on the latest advancements and innovations, including daridorexant, which presents a novel approach to treating insomnia while avoiding common side effects associated with traditional medications.